Pirche AG, a digital molecular risk assessment leader, unveiled a collaboration to enhance transplant medicine and immunosuppression. Teaming up with Natera, Inc., a global cell-free DNA testing and precision medicine leader, they intend to elevate patient care by linking pre-transplant immunological risk assessment with post-transplant monitoring via Natera's Prospera™ test. This strategic partnership aims to revolutionize transplant procedures, ultimately benefitting the patients. No specific financial figures were disclosed in the announcement.